De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product

Posted on by

BRISBANE, Australia, July 17, 2024 /PRNewswire/ — De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites. These expansion…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.